Logo

AbbVie Entered into a Co-Development & License Agreement with Gedeon Richter to Develop & Commercialize Dopamine Receptor Modulators for Neuropsychiatric Diseases

Share this
AbbVie Entered into a Co-Development & License Agreement with Gedeon Richter to Develop & Commercialize Dopamine Receptor Modulators for Neuropsychiatric Diseases

AbbVie Entered into a Co-Development & License Agreement with Gedeon Richter to Develop & Commercialize Dopamine Receptor Modulators for Neuropsychiatric Diseases

Shots:

  • Richter to receive an up front in cash & is eligible to receive development, regulatory & commercialization milestones along with sales-based royalties. The transaction is expected to be close in Q2’22
  • AbbVie gets the commercialization rights globally excluding traditional markets of Richter including EU, Russia, other CIS countries & Vietnam. The companies are expected that new products can reduce the psychiatric & cognitive symptoms of neuropsychiatric conditions
  • The collaboration was based on preclinical research including multiple new chemical entities selected for development. The companies collaborated for 15yrs. on CNS projects including globally launched products i.e., Vraylar/Reagila

Ref:  AbbVie | Image: AbbVie

Click here to­ read the full press release 

Neha

Neha Madan is a content writer at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions